HealthTech For Care and EIT Health publish the agenda of the 3rd edition of the HealthTech Innovation Days event next 4 & 5 October 2021

05 July 2021 - Federchimica Assobiotec is one of the partner of this 3rd edition of the HealthTech Innovation Days (HTID®), placed under the High Patronage of Emmanuel Macron, President of the French Republic. The European healthcare ecosystem will gather around tomorrow's health major challenges: Artificial Intelligence, health data regulation, impact of the Covid-19 crisis and antibiotic resistance or robotics. The HTID mobilises both international sponsors and European clusters.

For this 3rd edition of the HealthTech Innovation Days (HTID®), placed under the High Patronage of Mr Emmanuel Macron, President of the French Republic, the European healthcare ecosystem will gather around tomorrow's health major challenges: Artificial Intelligence, health data regulation, impact of the Covid-19 crisis and antibiotic resistance or robotics. The HTID mobilises both international sponsors and European clusters.

The event aims at widely sharing current thinking and actions with leaders in health innovation, global pharmaceutical companies, investors, political representatives and patient organisations. This event, which will again take place in a hybrid format, will also bring together several hundred dedicated healthtech investors and will offer face-to-face and remote meetings between investors from all over the world, European healthtech companies and pharmaceutical groups, with the aim of creating partnerships to speed the time-to-market of innovations for patients.





Find out more about the main themes of the programme:

Policy & Financing issues: what are the political and economic consequences of the Covid-19 crisis for the health sector in Europe?

The technological challenges of tomorrow: what market access for solutions based on Artificial Intelligence and Robotics? The European Parliament and Council reached a provisional agreement on Tuesday 22 June 2021 on health technology assessment (HTA), to help Member States make "faster evidence-based decisions on patient access" to their health systems.

Major therapeutic challenges: the European Commission has unveiled its plan to fight cancer: 4 billion euros to fund prevention, research and treatment deployment programmes across the EU. By 2050, antibiotic resistance could kill more people than cancer. The World Bank also estimates that the financial impact of antibiotic resistance by 2050 would be comparable to that of the 2008 financial crisis.

Accelerating innovation in health by providing cross-cutting solutions: the Covid crisis has highlighted the importance of innovation in the health sector. This applies both to clinical research (finding vaccines and treatments) and to the architecture of the healthcare system. In particular, cooperation between public and private players must be encouraged and innovation approaches centred on patient use must be integrated.

How to attract, recruit and train the talents of tomorrow in the health sector? In order to adapt to new technologies and to the ageing of the population, healthcare professions are changing rapidly. While pharmaceutical laboratories and biotech companies were already facing a shortage of talents, the Covid-19 crisis triggered a highly targeted demand that revealed an over-reliance on foreign production.

The use of patient health data for innovation: sharing conclusions of the HealthTech For Patients event which brought together a panel of European actors and experts from the health ecosystem around the theme of health data for medical innovation. Indeed, health data are essentials to accelerate the development of innovative solutions for the patient and require global support from the ecosystem, both financial and industrial.

The 3rd edition of the HTID benefits from the support of sponsors among major global industrial groups such as Amgen, Bristol-Myers Squibb, Microsoft, Sanofi, Servier, influential players in healthtech, such as Dechert, Financière Arbevel, Icosa, Invest Securities, Sofinnova Partners, as well as institutional partners such as Bpifrance, Euronext and Leem (Les Entreprises du Médicament), which allow for the gathering of all the experts around the themes addressed.

PRESS RELEASE

Where to find us

20149 Milan
Via Giovanni da Procida, 11
Show map 
Tel. +39 02.34565.1
Fax. +39 02.34565.310
Segreteria Assobiotec
Tel. 02 34565.256/341
assobiotec@federchimica.it